For the quarter ended December 2024, Nektar Therapeutics (NKTR) reported income of $29.18 million, up 22.1% over the identical interval final yr. EPS got here in at $0.15, in comparison with -$0.22 within the year-ago quarter.
The reported income represents a shock of -25.23% over the Zacks Consensus Estimate of $39.02 million. With the consensus EPS estimate being -$0.13, the EPS shock was +215.38%.
Whereas traders scrutinize income and earnings modifications year-over-year and the way they examine with Wall Road expectations to find out their subsequent transfer, some key metrics at all times supply a extra correct image of an organization’s monetary well being.
Since these metrics play a vital position in driving the top- and bottom-line numbers, evaluating them with the year-ago numbers and what analysts estimated about them helps traders higher undertaking a inventory’s value efficiency.
Right here is how Nektar carried out within the simply reported quarter by way of the metrics most generally monitored and projected by Wall Road analysts:
- Income- Product gross sales: $12.87 million versus the eight-analyst common estimate of $9.76 million. The reported quantity represents a year-over-year change of +134.8%.
- Income- Non-cash royalty income associated to sale of future royalties: $16.24 million versus $15.15 million estimated by eight analysts on common. In comparison with the year-ago quarter, this quantity represents a -10.1% change.
- Income- License, collaboration and different income: $0.06 million versus the four-analyst common estimate of $28.26 million. The reported quantity represents a year-over-year change of -81.5%.
View all Key Company Metrics for Nektar here>>>
Shares of Nektar have returned +23.5% over the previous month versus the Zacks S&P 500 composite’s -8.2% change. The inventory at present has a Zacks Rank #2 (Purchase), indicating that it might outperform the broader market within the close to time period.
5 Shares Set to Double
Every was handpicked by a Zacks skilled because the #1 favourite inventory to achieve +100% or extra in 2024. Whereas not all picks could be winners, earlier suggestions have soared +143.0%, +175.9%, +498.3% and +673.0%.
Many of the shares on this report are flying beneath Wall Road radar, which offers an amazing alternative to get in on the bottom flooring.
Today, See These 5 Potential Home Runs >>
Nektar Therapeutics (NKTR) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
The views and opinions expressed herein are the views and opinions of the creator and don’t essentially mirror these of Nasdaq, Inc.
